Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

Duo

Financiado

Duo A minimally invasive device to treat all patients with tricuspid valve dise...

Heart failure is the leading cause of death, affecting 15 million patients across Europe and the US. In patients with heart failure, the right heart expands, resulting in the tricuspid valve not closing properly and blood leaking... ver más

30/11/2023

CROIVALVE

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

CROIVALVE LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 5 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-11-30

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

EIC-FTI-2018-2020: Fast Track to Innovation (FTI)

I+D

Cerrada hace 6 años

0% 100%

5 Participantes

CROIVALVE

1.90M€ | Lider

SAT NUMERO 8275 QUESOS FLOR...

217.19K€ | Participante

ICS Med Devices

480.18K€ | Participante

Syntactx Europe

460.11K€ | Participante

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 42 meses Fecha Inicio: 2020-05-13
Fecha Fin: 2023-11-30

Líder del proyecto

CROIVALVE LIMITED

TRL 4-5

Presupuesto del proyecto 4M€

Descripción del proyecto Heart failure is the leading cause of death, affecting 15 million patients across Europe and the US. In patients with heart failure, the right heart expands, resulting in the tricuspid valve not closing properly and blood leaking backwards. This is called tricuspid regurgitation. The tricuspid valve has remained largely untreated due to unique functional and anatomical challenges. Currently less than 1% of patients are surgically treated due to the fact that open-heart surgery is still the only treatment option and is very risky. As a result, these patients face worsening quality of life with 60% of patients not surviving past 3 years. The Duo project aims to enable the commercialisation of a minimally invasive device that restores the function of the tricuspid valve in a safe and effective manner for all patients with TR. An innovative adjustable anchor holds the device in position between the tricuspid valve leaflets, anchored against the venous wall, where it does not touch the fragile cardiac tissue. This multi-disciplinary consortium of innovative SME’s is uniquely positioned to accelerate bringing this disruptive technology to market. CroiValve, the consortium coordinator, was founded specifically to develop and commercialise a minimally invasive tricuspid treatment. ICS Medical is an expert in the design, development and manufacturing of complex catheter solutions. Syntactx is a full-service CRO that understands how to deliver efficient and good quality clinical data. 3D LaserTec is an innovation driven centre for laser cut parts. With Fast Track to Innovation funding, the consortium will finalise the development of the Duo-TF device and develop US clinical evidence demonstrating the clinical benefits of Duo to the patient. This will position Duo as the gold standard treatment, thus saving the lives of thousands of patients and reducing this significant healthcare burden. The project will also enable Europe to take the lead in the large tricuspid €2.5Bn/year market.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores